Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation

Hann Hsiang Chao, Ilias V. Karagounis, Christoforos Thomas, Noëlle B. François, Andrea Facciabene, Constantinos Koumenis, Amit Maity

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

We explore a novel strategy of activating immune signaling through increased micronuclei formation utilizing a cell cycle checkpoint inhibitor to drive cell cycle progression following ionizing radiation. The Chk1/2 inhibitor AZD7762 is used to abrogate radiation therapy (RT)-induced G2/M cell cycle arrest in multiple cell lines and, we find that this therapeutic combination promotes increased micronuclei formation in vitro and subsequently drives increased type I interferon signaling and cytotoxic T-cell activation. In vivo studies using B16-F10 melanoma cancer cells implanted in C57/BL6 mice demonstrate improved rates of tumor control at the abscopal (unirradiated) site, located outside of the radiation field, only in the AZD7762 + RT group, with a corresponding reduction in mean tumor volume, increase in the CD8 T-cell population, and immune activated gene signaling. Our results demonstrate that targeted inhibition of cell cycle checkpoint activation following ionizing radiation drives increased production of immunogenic micronuclei, leading to systemic tumor response with potential future clinical benefit.

Original languageEnglish (US)
Pages (from-to)4344-4357
Number of pages14
JournalOncogene
Volume39
Issue number22
DOIs
StatePublished - May 28 2020

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Fingerprint

Dive into the research topics of 'Combination of CHEK1/2 inhibition and ionizing radiation results in abscopal tumor response through increased micronuclei formation'. Together they form a unique fingerprint.

Cite this